533939-04-7

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine,6-ethyl-(9CI)
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine,6-ethyl-(9CI);1H-Pyrrolo[2,3-b]pyridine, 6-ethyl-;6-ethyl-1H-pyrrolo[2,3-b]pyridine;1H-Pyrrolo[2,3-B]Pyridine, 6-Ethyl-(WX690052)
• CAS NO: 533939-04-7
• Molecular Formula: C9H10N2
• Molecular Weight: 146.19
• Product Categories: PYRIDINE
• Mol File: 533939-04-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 272.3°C at 760 mmHg
• Flash Point: 116.3°C
• Appearance: /
• Density: 1.142g/cm³
• Vapor Pressure: 0.0102mmHg at 25°C
• Refractive Index: 1.641
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine,6-ethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine,6-ethyl-(9CI)(533939-04-7)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine,6-ethyl-(9CI)(533939-04-7)

Safety Data

• Hazardous Substances Data: 533939-04-7(Hazardous Substances Data)

Usage

CAS Registry Number

63435-28-1

Type of Compound

Heterocyclic organic compound

Usage

Building block for various drugs and biologically active compounds in pharmaceutical and organic synthesis

Unique Value

Valuable component in the development of new therapeutic agents and drug discovery research due to its unique structure and properties.

InChI:InChI=1/C9H10N2/c1-2-8-4-3-7-5-6-10-9(7)11-8/h3-6H,2H2,1H3,(H,10,11)

Upstream product

• 4433-63-0 Ethyl boronic acid 
• 143468-07-9 6-Chloro-1-methoxycarbonyl-1H-pyrrolo<2,3-b>pyridine 
• 849068-50-4 ethyl 6-chloro-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 1378685-98-3 C₉H₁₂N₂O 

Downstream Products

• 533939-05-8 6-ethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl-dimethyl-amine 
• 1420532-25-7 N-ethyl-N-(2-(6-ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)cyclopropanecarboxamide 
• 1420532-26-8 ?N-(2-(3-bromo-6-ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)-N-ethylcyclopropanecarboxamide 

Relevant articles and documents

Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket

In the development of kinase inhibitors, one of the major concerns is selectivity. An effective strategy to achieve high selectivity is to utilize structural differences among kinases to inform inhibitor design. Here, we set out to improve the PIM (proviral integration site for Moloney murine leukemia virus) kinase-inhibitory selectivity of our previously reported 7-azaindole derivative 2, which has promising ADMET properties, by targeting a unique bulge in the ATP-binding pocket. 6-Substituted 7-azaindoles, especially the 6-chlorinated derivatives, proved to be potent and selective PIM kinase inhibitors and appear to be promising lead compounds for future drug discovery.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Substituted heteroarylalkanoic acids

Disclosed are substituted heteroarylalkanoic acids acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.